secwatch.observer — SEC 8-K summary
======================================

Issuer:     Autonomix Medical, Inc. (AMIX)
CIK:        0001617867
Form:       8-K
Filed at:   2024-08-13T23:59:59+00:00
Accession:  0001437749-24-026162
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Autonomix Medical reports Q1 FY2025 net loss $2.7M, positive 7-day pain relief data from lead-in patients
--------------------------------------------------------------------------------

- Net loss $2.7M vs $0.9M YoY; cash $6.8M as of June 30, 2024.
- G&A $1.8M (up $1.3M) and R&D $1.0M (up $0.6M) driven by compensation and clinical costs.
- 60% of first five lead-in patients had mean 6.33 VAS pain reduction (from 8.0 to 1.67) at 7 days.
- Appointed Brad Hauser CEO; licensed RF Innovations' FDA-cleared Apex 6 ablation generator.
- Expects topline PoC trial data 1H CY2025, FDA de novo submission 2026, clearance 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1617867/000143774924026162/0001437749-24-026162-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1617867/000143774924026162/amix20240812_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-026162

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer